Evidence level: C
阿育吠陀三质与生理通路的交互效应到底有多大,必须用先导数据或已发表研究反推真实量级,而不是沿用”约为主效应 1/3-1/5″这条从未实测过的外推先验。
正文
三质(瓦塔/皮塔/卡法)研究里有一条反复出现的量级假设:体质与生理通路的交互效应,大约是主效应的 1/3 到 1/5。这个数字决定了整个交叉实验设计的规模——12 格三质×四通路交叉(自主神经、炎症信号、脑肠反射、边缘/皮层活动)每格 n≥15 就是按它倒推出来的。但问题在于:这个 1/3-1/5 至今没有任何实测来源,是从”体质调制通路反应”的机制直觉直接外推出来的量级先验。先验错了,整套设计就白跑。
为什么不能直接信这个先验。 第一,生理学里交互效应典型偏小:全基因组方差 QTL 分析血压性状显示,交互项解释的方差远小于主效应项(PMID 35879408)。第二,交互检验本身就是功效洼地——Brookes 等对随机试验亚组分析的系统梳理表明,检验主效应交互所需的样本量约是主效应检验的数倍(PMID 15066682),且连续变量交互的显著性高度依赖分析方法(PMID 23580422)。第三,小样本估计交互项会系统性膨胀:神经科学领域的全景审计显示,小样本研究的效应量点估计平均被噪声抬高约三成(PMID 23571845)——在 n≈15 的格子里直接读交互项点估计,得到的比值可能忽大忽小。第四,先导研究本来就不擅长估准设计参数:模拟研究显示,要在外部先导试验里把方差等设计参数估到可用精度,所需样本量远超惯例(PMID 24993581),而现实中先导研究的样本量普遍低于这个门槛(PMID 37990337)。
标定设计分三层。 A 层是已发表数据反推:对四条件吟诵实验(大声吟诵/只动口型/静默吟诵/不吟诵,PMID 40547334)的原始数据重建模,把个体体质代理变量×实验条件的交互项做效应量点估计,配 2000 次 bootstrap 置信区间;同法处理三质失衡的 HRV 探索研究(PMID 29269119)。这一层零成本,只是把别人已经付过钱的交互信息挖出来。B 层是先导小样本交叉:三质分型×四通路终点,每格 n≥15,主报告就是交互项效应量点估计加 bootstrap 置信区间——注意是区间,不是点。C 层是功效曲面:把比值梯度(1/2、1/3、1/5、1/10)逐档代入功效公式,画出每档所需的样本量曲面,直接回答”12 格交叉在可负担样本量内是否可行”这个设计存亡问题。
为什么每格 n≥15 只是下限,不是安全线。 交互项的标准误天然比主效应大:两个变量的乘积项引入额外方差,同样的样本量下交互检验的功效显著更低(PMID 15066682)。这意味着”每格 15 人、12 格共 180 人”的配置,只够把主效应估到可用精度,交互项的置信区间可能宽到无法判读。更麻烦的是体质分型本身的错分噪声:标签信度不足会把真实交互稀释向零,样本量曲面上还要叠加一条”标签翻转率×衰减”的修正。因此 B 层先导的正确读法是:它不是设计终审,而是把交互效应量的置信区间从”完全不知道”压缩到”够窄、够便宜地决定下一步怎么走”。如果 A 层反推已经给出足够窄的区间,B 层甚至可以跳过——省下的预算全部投给功效曲面标定过的正式交叉实验。
判决式预注册。 实测比值落在 1/3-1/5 区间内,则该先验升级为有实测支撑的设计参数,12 格交叉按原样推进;实测远小于 1/5(如 <1/10),则宣告交互先验不可行,12 格交叉改写为”主效应+个体异质性建模”路线——治疗效应异质性的预测建模已有成熟的文献谱系可承接(PMID 33096986),且异质性度量口径本身就会改变结论(绝对效应量与相对效应量的判读可以方向相反,PMID 41317377),口径必须预注册;置信区间跨越零且下界超过 1/5,则判定”当前证据下不可裁决”,交互先验整体降级待证。无论哪种结局,后续实验设计都以实测曲线为准,不再引用这条口号。
证据与局限
已验证: 锚点研究的存在性与主效应量级(PMID 40547334 四条件交叉;PMID 29269119 dosha-HRV 探索研究);交互效应典型偏小的跨域证据(PMID 35879408);交互检验功效劣势与样本量倍增规律(PMID 15066682);小样本效应量膨胀(PMID 23571845)。
部分验证: 先导研究估设计参数所需样本量的模拟结论(PMID 24993581)与先导样本量现状综述(PMID 37990337);连续变量交互的方法依赖性(PMID 23580422)——均为一般方法学结论,尚未在三质场景复制。
待验证: “交互=主效应 1/3-1/5″这条量级先验本身;三质×四通路 12 格交叉在该效应量级下的可行性与功效曲面;体质代理变量在已发表数据反推中的测量信度。
相关阅读
L1 网络状态:该主题尚未进入 L1 对应网络。L1 边表仅有相邻 dosha 系列背景边(
assr-signature-vs-dosha-bowl-selection/ PMID 29269119,A级;ayurveda-dosha-pathway-blinded-head-to-head-/ PMID 24191170,B级),无「三质×通路交互效应量级」裁决边,本文证据等级据此封顶 C。证据等级: C
参考文献: PMID 40547334, PMID 29269119, PMID 35879408, PMID 15066682, PMID 23571845, PMID 24993581, PMID 37990337, PMID 23580422, PMID 33096986, PMID 41317377
证据等级:A=有PubMed直接支撑,B=科学类比/间接证据,C=传统文化共识/初步探索
免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。
Prior empirical calibration of the magnitude of the triad × pathway interaction effect: \”Interaction = 1/3 to 1/5 of the main effect\” remains merely a slogan
Evidence level: C
The magnitude of the interaction between Ayurvedic three qualities and physiological pathways must be inferred from pilot data or published research to establish the true scale, rather than relying on the extrapolated prior “approximately one-third to one-fifth of the main effect,” which has never been empirically measured.
Body
In Yijing Studies, the three constitutions (Vata/Pitta/Kapha) research repeatedly invokes a magnitude assumption: the interaction effect between constitution and physiological pathways is approximately 1/3 to 1/5 of the main effect. This ratio determines the scale of the entire crossover experimental design—12-grid three-constitution × four-pathway cross (autonomic nervous system, inflammatory signaling, brain-gut reflex, limbic/cortical activity) with n≥15 per grid is back-calculated from this assumption. However, the problem is: this 1/3–1/5 ratio has no empirical source to date; it is a magnitude prior directly extrapolated from the mechanistic intuition of “constitution-modulated pathway response.” If this prior is wrong, the entire design is futile.
Why one cannot simply trust this prior. First, in physiology, interaction effects are typically small: whole-genome variance QTL analysis of blood pressure traits shows that the variance explained by interaction terms is far smaller than that of main effect terms (PMID 35879408). Second, interaction testing itself is a power pitfall—Brookes et al.’s systematic review of subgroup analyses in randomized trials indicates that the sample size required to test main-effect interactions is several times larger than that for testing main effects alone (PMID 15066682), and the significance of continuous-variable interactions heavily depends on the analytical method (PMID 23580422). Third, small-sample estimation of interaction terms systematically inflates effect sizes: a panoramic audit in neuroscience reveals that point estimates of effect size in small-sample studies are on average inflated by about 30% due to noise (PMID 23571845)—reading the interaction term point estimate directly from grids with n≈15 may yield ratios that fluctuate wildly. Fourth, pilot studies are inherently poor at estimating design parameters accurately: simulation research shows that to estimate variance-equivalent design parameters to usable precision in external pilot trials, the required sample size far exceeds convention (PMID 24993581), while in reality, pilot studies universally have sample sizes well below this threshold (PMID 37990337).
The design calibration proceeds in three layers. Layer A is reverse-engineering from published data: reconstructing raw data from the four-condition chanting experiment (loud chanting, silent mouthing, quiet chanting, no chanting; PMID 40547334) and modeling individual constitution proxies × experimental condition interactions to obtain point estimates of effect size, accompanied by 2000-bootstrap confidence intervals; similarly applied to the HRV exploration study on three-constitution imbalance (PMID 29269119). This layer incurs zero cost, merely excavating interaction information already paid for by others. Layer B is the pilot small-sample crossover: three-constitution typing × four-pathway endpoints, with n≥15 per grid; the main report presents point estimates of interaction effect sizes plus bootstrap confidence intervals—note that these are intervals, not points. Layer C is the power surface: substituting ratio gradients (1/2, 1/3, 1/5, 1/10) sequentially into the power formula to plot the required sample size surface for each tier, directly answering whether “the 12-grid crossover is feasible within affordable sample sizes”—this determines the survival of the design.
Why n≥15 per grid is merely a lower bound, not a safety line. The standard error of interaction terms is naturally larger than that of main effects: the product term of two variables introduces additional variance, so under the same sample size, the power for testing interactions is significantly lower (PMID 15066682). This means that a configuration of “15 people per grid, totaling 180 across 12 grids” is sufficient only to estimate main effects to usable precision; the confidence intervals for interaction terms may be so wide as to be uninterpretable. More problematically, misclassification noise inherent in constitution typing dilutes true interactions toward zero: insufficient label reliability attenuates the real interaction effect, and the sample size surface must additionally incorporate a correction term for “label flip rate × attenuation.” Therefore, the correct reading of Layer B pilots is: they are not the final design decision, but rather compress the confidence interval of interaction effect sizes from “completely unknown” to “narrow enough and cheap enough to decide the next step.” If Layer A reverse-engineering already yields sufficiently narrow intervals, Layer B can be skipped entirely—the saved budget should be fully invested in the formal crossover experiment calibrated by the power surface.
Decisive pre-registration. If the measured ratio falls within the 1/3–1/5 interval, this prior is upgraded to an empirically supported design parameter, and the 12-grid crossover proceeds as originally planned. If the measured ratio is far smaller than 1/5 (e.g., <1/10), the interaction prior is declared infeasible, and the 12-grid crossover is rewritten as a “main effect plus individual heterogeneity modeling” route—prediction modeling of treatment effect heterogeneity already has an established literature lineage to support (PMID 33096986), and the metric of heterogeneity itself alters conclusions (absolute effect size vs. relative effect size can lead to opposite interpretations, PMID 41317377); the metric must be pre-registered. If the confidence interval crosses zero with its lower bound exceeding 1/5, the design is judged “undecidable under current evidence,” and the interaction prior is downgraded pending further proof. Regardless of outcome, subsequent experimental design follows the measured curve, and this slogan is no longer cited.
Evidence and Limitations
Verified: Existence of anchor studies and magnitude of main effects (PMID 40547334 four-condition crossover; PMID 29269119 dosha-HRV exploratory study); typical cross-domain evidence for interaction effects being small (PMID 35879408); power disadvantage of interaction tests and the sample size doubling rule (PMID 15066682); inflation of effect sizes in small samples (PMID 23571845).
Partially Verified: Simulation conclusions on sample size requirements for pilot studies (PMID 24993581) and current review of pilot sample sizes (PMID 37990337); method dependence of continuous variable interactions (PMID 23580422)—all general methodological conclusions, not yet replicated in the three-quality scenario.
Pending Verification: The magnitude prior itself (“interaction = 1/3 to 1/5 of main effect”); feasibility and power surface of the three-quality × four-pathway 12-cell crossover at this effect magnitude; measurement reliability of constitution proxy variables in back-calculations from published data.
Related Reading
- Three Constitutions ΔAUC Head-to-Head Minimum Detectable Effect and Sample Size Feasibility Boundaries
- Three-Factor “Constitution Label vs. Imbalanced State” Dual-Model Separation Arbitration
- Cross-Cultural Frequency Cognition Research Pool
L1 Network Status: This topic has not yet entered the corresponding L1 network. The L1 edge list contains only adjacent dosha series background edges (
assr-signature-vs-dosha-bowl-selection/ PMID 29269119, evidence level A;ayurveda-dosha-pathway-blinded-head-to-head-/ PMID 24191170, evidence level B), with no “Three Constitutions × Pathway Interaction Effect Magnitude” arbitration edge. Consequently, the evidence level for this article is capped at C.Evidence Level: C
References: PMID 40547334, PMID 29269119, PMID 35879408, PMID 15066682, PMID 23571845, PMID 24993581, PMID 37990337, PMID 23580422, PMID 33096986, PMID 41317377
Evidence level: A = directly supported by PubMed, B = scientific analogy/indirect evidence, C = traditional consensus/preliminary exploration.
Disclaimer: This article compiles traditional knowledge and scientific literature for comparison and research-design discussion only. It is not medical advice and cannot replace professional diagnosis or treatment. Effect sizes, frequency ranges and exposure conclusions cited here are largely inferences at the research-report level, and individual circumstances vary widely. If you have any discomfort or health concerns, please consult a physician.